Uniprogen Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.05 Cr
as on 03-07-2024
- Paid Up Capital ₹ 1.01 Cr
as on 03-07-2024
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Mar 2021
- Revenue -30.19%
(FY 2020)
- Profit 78.85%
(FY 2020)
- Ebitda 63.62%
(FY 2020)
- Net Worth -8.83%
(FY 2020)
- Total Assets 43.37%
(FY 2020)
About Uniprogen Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.05 Cr and a paid-up capital of Rs 1.01 Cr, as per Ministry of Corporate Affairs (MCA) records.
Priyajit Chakraborty, Nilesh Chaubey, Madhu Mehta, and Three other members serve as directors at the Company.
- CIN/LLPIN
U51909MH2010PTC198320
- Company No.
198320
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jan 2010
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Navi Mumbai, Maharashtra, India
- Telephone
- Email Address
- Social Media-
Who are the key members and board of directors at Uniprogen Biotech?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Boomi Shankar  | Director | 02-Jan-2010 | Current |
| Priyajit Chakraborty | Additional Director | 19-Mar-2020 | Current |
| Nilesh Chaubey | Director | 03-Aug-2018 | Current |
| Madhu Mehta | Director | 01-Apr-2013 | Current |
| Anandkumar Singh | Director | 15-Jan-2010 | Current |
| Santanu Nayak | Director | 15-Jan-2010 | Current |
Financial Performance and Corporate Structure Insights of Uniprogen Biotech.
Uniprogen Biotech Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 30.19% decrease. The company also saw a substantial improvement in profitability, with a 78.85% increase in profit. The company's net worth dipped by a decrease of 8.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Uniprogen Biotech?
In 2021, Uniprogen Biotech had a promoter holding of 98.50% and a public holding of 1.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Uniprogen Biotech?
Uniprogen Biotech has a workforce of 3 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Uniprogen Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Uniprogen Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
